Last updated
PT-141 and Melanotan II are not rivals so much as parent and offspring: bremelanotide (PT-141) is the active metabolite of Melanotan II, and the story of how one became the other is a lesson in what receptor selectivity buys you. One is FDA-approved for sexual desire; the other is an unapproved, non-selective tanning peptide.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | PT-141 | Melanotan II |
|---|---|---|
| Structure | Cyclic heptapeptide, C-terminal free acid (-OH) | Cyclic heptapeptide, C-terminal amide (-NH2) |
| Relationship | Active metabolite of Melanotan II | The parent compound |
| Receptor profile | MC4R-preferential | Non-selective: MC1R / MC3R / MC4R / MC5R |
| Primary effect | Central sexual arousal (MC4R) | Pigmentation (MC1R) + MC4R central effects |
| Tanning activity | Not the target (refined away from MC1R) | Yes — its best-known use |
| FDA status | Approved (Vyleesi, 2019, HSDD in premenopausal women) | Not approved |
| Known side effects | Nausea, flushing, transient BP rise | Nausea, flushing, spontaneous erections, mole/freckle darkening |
| Origin | Palatin Technologies (Molinoff / Diamond et al., 2003) | University of Arizona |
Melanotan II was developed at the University of Arizona as a non-selective α-MSH analog — it activates all four melanocortin receptors from MC1R to MC5R. Through MC1R it drives pigmentation, which is what it became known for; but through MC4R it also acts on central sexual-response circuits, and in early human studies that MC4R activity showed up as spontaneous erections alongside nausea and flushing. Those “side effects” were the clue: the arousal signal could be separated from the tan.
PT-141 (bremelanotide) is what that separation looks like chemically. It is the active metabolite of Melanotan II, differing by a single change at the C-terminus — an amide (-NH2) replaced by a free acid (-OH) — which shifts the molecule’s preference toward MC4R and away from the MC1R-driven pigmentation. Refined that way and developed for central arousal, it became FDA-approved (Vyleesi, 2019) for hypoactive sexual desire disorder in premenopausal women. Melanotan II, non-selective and carrying the pigmentation and off-target effects that selectivity removes, never gained approval.
This is a textbook case of selectivity turning a research peptide into an approved drug. Melanotan II is the non-selective parent — pigmentation plus MC4R effects plus the off-target profile that comes with hitting every melanocortin receptor. PT-141 is the MC4R-preferential metabolite, refined toward sexual desire and cleaned up enough to reach approval for a specific indication. They share a core structure, but only one is a characterized, approved medicine; the other remains an unapproved, gray-market compound. This page is a research and educational reference, not a usage recommendation.
Melanotan II is a non-selective melanocortin agonist (MC1R–MC5R) best known for pigmentation, and it is not approved. PT-141 (bremelanotide) is its active metabolite, refined toward the MC4R receptor and central sexual arousal, and it is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Yes. Bremelanotide (PT-141) is the active metabolite of Melanotan II, differing by a single C-terminal change — an amide replaced by a free acid — which shifts its receptor preference toward MC4R and away from the MC1R pigmentation activity. Its development followed the observation that Melanotan II produced arousal effects via MC4R.
Tanning is not its purpose. PT-141 is refined toward MC4R and away from the MC1R activity that drives pigmentation, so it is studied and approved for sexual desire rather than as a tanning agent. Melanotan II is the non-selective one that produces the tan.
PT-141 (bremelanotide) is FDA-approved as Vyleesi (2019). Melanotan II is not approved. This page is a research and educational reference, not medical advice or a usage recommendation.
Mechanism, evidence, and trade-offs between PT-141 and Melanotan II — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.